ENSURE in AF: Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Parallel Group Study Comparing Edoxaban with Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned electrical cardioversion of nonvalvular atrial fibrillat
-
Location(s): Czech Republic
Description
A prospective, randomised, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of nonvalvular atrial fibrillation